Want to see TSE:LCR full AI Analyst Report?
Top Page
NeonMind Biosciences Inc
(LCR)
Select Model
Select Model
Rating:41Neutral
Price Target:
C$0.02
▲(20.00% Upside)
Action:Reiterated
Date:09/06/26
The score is weighed down primarily by very weak financial performance (no revenue, persistent losses, negative equity, and ongoing cash burn), which increases financing and continuity risk. Technicals add modest pressure due to a longer-term downtrend (price below 100/200-day averages), partially offset by oversold readings. Valuation offers limited support because the company is loss-making (negative P/E) and no dividend yield is provided.
Positive Factors
Lower cash burn
A lower cash-burn rate indicates tighter spending and can extend the company’s operating runway compared with prior years. Although NeonMind remains a net cash user, improved cost control may reduce the pace of external funding needs while management works toward a viable operating model.
Negative Factors
No demonstrated revenue base
Persistent zero reported revenue means the company has not demonstrated commercial traction or a functioning revenue engine across the periods provided. Without operating sales, future progress remains dependent on developing and commercializing activities rather than compounding from an established customer base.
Read all positive and negative factors
Positive Factors
Negative Factors
Lower cash burn
A lower cash-burn rate indicates tighter spending and can extend the company’s operating runway compared with prior years. Although NeonMind remains a net cash user, improved cost control may reduce the pace of external funding needs while management works toward a viable operating model.
Read all positive factors
NeonMind Biosciences Inc (LCR) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$2.72M
Dividend YieldN/A
Average Volume (3M)39.82K
Price to Earnings (P/E)―
Beta (1Y)1.26
Revenue GrowthN/A
EPS Growth57.03%
CountryCA
EmployeesN/A
SectorBasic Materials
Sector Strength58
IndustryIndustrial Materials
Share Statistics
EPS (TTM)-0.01
Shares Outstanding108,819,870
10 Day Avg. Volume48,450
30 Day Avg. Volume39,818
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)-9.40
Price to Sales (P/S)0.00
P/FCF Ratio-6.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
NeonMind Biosciences Inc Business Overview & Revenue Model
Company Description
Lancaster Resources Inc. focuses on acquiring, exploring, and advancing both mineral deposits and sustainable energy initiatives. A notable asset for the company is its exclusive right to acquire full ownership of the Alkali Flat lithium brine pro...
NeonMind Biosciences Inc Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
8
Very Negative
Cash Flow
12
Very Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Mar 2024 | Feb 2023 | Feb 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -883.16K | -1.58M | -897.00 | ― | -1.75M | -7.83M |
| Net Income | -1.14M | -1.75M | -1.54M | ― | -2.03M | -7.21M |
Balance Sheet | ||||||
| Total Assets | 1.04M | 1.09M | 91.12K | 719.33K | 129.43K | 1.34M |
| Cash, Cash Equivalents and Short-Term Investments | 37.43K | 206.03K | 13.98K | 135.40K | 69.91K | 967.27K |
| Total Debt | 1.27M | 1.14M | 1.19M | 1.04M | 846.94K | 450.01K |
| Total Liabilities | 2.16M | 1.74M | 2.00M | 1.33M | 1.53M | 1.05M |
| Stockholders Equity | -1.09M | -635.18K | -1.90M | -612.89K | -1.40M | 290.30K |
Cash Flow | ||||||
| Free Cash Flow | -473.62K | -988.65K | -89.79K | -1.31M | -1.22M | -5.82M |
| Operating Cash Flow | -487.92K | -988.66K | -89.79K | -1.13M | -1.08M | -5.82M |
| Investing Cash Flow | -285.39K | -129.42K | 37.60K | -36.15K | 72.14K | 389.12K |
| Financing Cash Flow | 631.83K | 1.29M | 0.00 | 627.93K | 271.00K | 6.20M |
NeonMind Biosciences Inc Technical Analysis
Negative
0.02
Price Trends
0.02
Negative
0.03
Negative
0.03
Negative
Market Momentum
>-0.01
Negative
30.35
Neutral
50.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:LCR, the sentiment is Negative. The current price of 0.02 is above the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and below the 200-day MA of 0.03, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 30.35 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:LCR.
NeonMind Biosciences Inc Peers Comparison
UnderperformOutperform
Sector (61)
TSE:LCR
NeonMind Biosciences Inc
0.03
-0.02
-37.50%
TSE:LSD.H
Lightspeed Discoveries
0.05
0.03
150.00%
TSE:LEXT
Lexston Life Sciences Corp.
0.07
-0.11
-61.76%
NeonMind Biosciences Inc Corporate Events
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresPrivate Placements and FinancingRegulatory Filings and Compliance
Lancaster Resources Shifts to Semi-Annual Reporting as It Launches Strategic Review
Negative
Sep 18, 2026
Lancaster Resources Inc. has adopted semi-annual financial reporting under a Canadian securities regulators’ pilot program, easing the administrative and financial burden of quarterly filings while maintaining annual and mid-year statements ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.